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In humans, circulating anti-neutrophil cytoplasm au-
toantibodies (ANCAs) with specificity for myeloper-
oxidase (MPO) are strongly associated with the devel-
opment of pauci-immune necrotizing and crescentic
glomerulonephritis (NCGN). In mice, we have dem-
onstrated that intravenous injection of mouse anti-
bodies specific for mouse MPO induces NCGN that
closely mimics the human disease. We now report
that the development of NCGN in this experimental
model is accompanied by glomerular accumulation of
neutrophils and macrophages. Neutrophil infiltration
was most conspicuous at sites of glomerular necrosis
and crescent formation, with macrophages also most
numerous in crescents. Lymphocytes, however, were
sparse in acute lesions. Importantly, mice that were
depleted of circulating neutrophils with NIMP-R14 rat
monoclonal antibodies were completely protected
from anti-MPO IgG-induced NCGN. These findings
provide direct evidence that neutrophils play a major
role in the pathogenesis of anti-MPO-induced NCGN
in this animal model and implicate neutrophils in the
induction of human ANCA disease. This raises the
possibility that therapeutic strategies to reduce circu-
lating neutrophils could be beneficial to patients
with ANCA-induced NCGN. (Am J Pathol 2005,
167:39–45)
Anti-neutrophil cytoplasm autoantibodies (ANCAs) are
specific for constituents of the primary granules of
neutrophils and the peroxidase-positive lysosomes of
monocytes.1 The two major antigen specificities are for
myeloperoxidase (MPO-ANCA) and proteinase 3 (PR3-
ANCA).1–3 ANCAs are found in 80 to 90% of patients with
necrotizing and crescentic glomerulonephritis (NCGN)
that is characterized immunohistologically by the ab-
sence or paucity of immunoglobulin in vessel walls (ie,
pauci-immune NCGN).1,4,5 ANCA NCGN is the most
common form of aggressive glomerulonephritis and often
is accompanied by a pauci-immune systemic necrotizing
small vessel vasculitis, such as microscopic polyangiitis
or Wegener’s granulomatosis.4–6
Numerous observations suggest that neutrophils are
important effector cells in the pathogenesis of human
ANCA NCGN. In renal biopsies from patients with ANCA
NCGN, activated neutrophils are present in affected glo-
meruli and in the renal interstitium.7 The number of acti-
vated intraglomerular neutrophils correlates with the se-
verity of renal injury as reflected in serum creatinine
levels.7 In vitro, ANCAs can activate cytokine-primed neu-
trophils, causing an oxidative burst, degranulation, re-
lease of inflammatory cytokines, and damage to endo-
thelial cells.8,9 Recently, our laboratory developed an
experimental animal model of NCGN that involves the
adoptive transfer of mouse anti-MPO lymphocytes
into immune-deficient mice or the passive infusion of
mouse anti-MPO IgG into either immune-deficient or
immune-competent mice.10 The resulting NCGN has
remarkable pathological similarity to human ANCA
glomerulonephritis.
In the current study, we investigated the hypothesis
that neutrophils are key effector cells in the pathogenesis
of MPO-ANCA-mediated NCGN in this experimental
model. The results show that anti-MPO-induced NCGN is
associated with the accumulation of neutrophils and
macrophages at sites of glomerular injury, and that neu-
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trophil-depleted mice are protected from induction of
NCGN by anti-MPO IgG. Taken together, these results
indicate that neutrophils play a major role in anti-MPO-
induced NCGN in this model.
Materials and Methods
Mice
Breeding pairs of C57BL/6J (B6) mice were purchased
from Jackson Laboratories (Bar Harbor, ME) and
maintained by the University of North Carolina Division
of Laboratory Animal Medicine. Mice lacking MPO
(MPO/ mice) were the sixth-generation progeny of a
backcross into B6 mice originally generated by Aratani
and colleagues.11 MPO/ mice (8 to 10 weeks old)
were used for immunization and as donors of anti-MPO
antibodies. Wild-type (WT) B6 mice (9 to 10 weeks old)
were used as recipients for passive transfer experiments.
The University of North Carolina Institutional Animal Care
and Use Committee approved all animal experiments.
Preparation of Pathogenic Mouse Anti-Murine
MPO IgG and Control Mouse Anti-Bovine
Serum Albumin (BSA) IgG
The purification of mouse MPO and the immunization
of MPO/ mice were performed as previously de-
scribed.10 Briefly, mouse MPO was purified from WEHI-3
cells by Dounce homogenization, Concanavalin A affinity
chromatography, ion exchange, and gel filtration chro-
matography. MPO/ mice were immunized intraperito-
neally with 10 g of purified murine MPO or BSA in
complete Freund’s adjuvant. Development of antibodies
was monitored by anti-MPO enzyme-linked immunosor-
bent assay. The presence of circulating anti-MPO anti-
bodies was confirmed in selected animals by indirect
immunofluorescence microscopy assay on murine neu-
trophils as described.10 The IgG fraction was isolated
from the serum of MPO/ mice immunized with murine
MPO by 50% ammonium sulfate precipitation and protein
G affinity chromatography as previously described.10
The IgG fractions were concentrated, sterilized by ultra-
filtration, and the protein concentrations were determined
by Coomassie protein assay reagent kit (Pierce, Rock-
ford, IL). The purity of the isolated antibodies was con-
firmed by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis.
Induction of Anti-MPO Disease
Two different regimens were used to produce anti-MPO-
induced glomerulonephritis. Studies of the effects of neu-
trophil depletion on induction of glomerulonephritis used
one intravenous injection of 50 g/g body weight of anti-
MPO IgG in phosphate-buffered saline (PBS) on day 0
with sacrifice on day 6. Control mice received the same
dose of anti-BSA or no IgG. For more detailed evaluation
of glomerular infiltration by neutrophils, a more severe
expression of disease was induced by a double dose of
anti-MPO IgG. The first intravenous 50 g/g body weight
dose of anti-MPO IgG was administered on day 0, the
second dose was administered on day 3, and the mice
were sacrificed on day 6. The control group of B6 mice
for this study received the same amount of anti-BSA IgG
on days 0 and 3. Induction of circulating anti-MPO was
monitored in all mice by anti-MPO enzyme-linked immu-
nosorbent assay.10
Laboratory and Pathological Evaluation of
Disease Induction
Five days after injection of anti-MPO and 1 day before
sacrifice, mice were placed in metabolic cages for 12
hours to collect urine for analysis. Urine was tested by
dipstick for hematuria, proteinuria, and leukocyturia
(Roche Diagnostics Corp., Indianapolis, IN). A reference
range was established from the urine analysis of 305
normal B6 mice, which had hematuria 0.1  0.4, protein-
uria 1.0  0.1, and leukocyturia 0.0  0.1. Thus, using the
mean plus 2 SDs for the reference range, abnormal he-
maturia was set at 0.9, proteinuria 1.2, and leukocy-
turia 0.2. Mice were euthanized on day 6 with methoxy-
flurane. At the time of postmortem examination, samples
of kidney were fixed in 10% formalin and processed for
light microscopy, or snap-frozen and processed for im-
munofluorescence microscopy. For light microscopy,
specimens were stained with hematoxylin and eosin, pe-
riodic acid-Schiff, and Masson trichrome stains. For im-
munofluorescence microscopy to detect glomerular lo-
calization of immune determinants, frozen sections were
stained with fluoresceinated antibodies specific for
mouse IgG, IgM, IgA, C3, and MPO (ICN/Cappel, Aurora,
OH). For detection of leukocytes in frozen tissue, sections
were stained with rat antibodies to neutrophils (anti-Gr-1,
clone RB6-8C5; BD Pharmingen, Franklin Lakes, NJ),
monocytes/macrophages (anti-F4/80 clone A3-1, Re-
search Diagnostics, Flanders, NJ; and anti-CD68, clone
FA11, Serotec, Raleigh, NC), and lymphocytes (anti-CD3,
clone KT3; Beckman Coulter, Fullerton, CA). Rat antibody
binding was detected using peroxidase-labeled second-
ary rabbit anti-rat IgG and tertiary goat anti-rabbit IgG
antibodies (DAKO, Carpinteria, CA). Staining was gener-
ated with 3-amino-9-ethylcarbazole and hydrogen perox-
ide. Sections were counterstained with hematoxylin. Leu-
kocyte localization was expressed as the average
leukocytes per cross-section of glomeruli based on eval-
uating an average of 48 glomeruli per specimen (range,
30 to 80 glomeruli). For more detailed evaluation of neu-
trophil infiltration in the mice that received two doses of
anti-MPO, immunostaining for neutrophils was performed
on 5-m paraffin sections of kidney using a biotin-labeled
rat monoclonal anti-mouse neutrophil antibody NIMP-R14
(Cedarlane Laboratories Ltd., Ontario, Canada) with de-
tection achieved with peroxidase-conjugated streptavi-
din (BioGenex, San Ramon, CA) and a DAKO Liquid
DAB substrate-chromogen system (DAKO, Carpinteria,
CA). A kidney from each of six mice that received two
doses of anti-MPO was evaluated at two levels of section
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at least 50 m apart for a total of 12 levels. Similarly, one
kidney from six mice that received two doses of anti-BSA
was evaluated at two levels of section for a total of 12
levels. Neutrophil accumulation was quantified by direct
counting of stained cells in glomeruli at each of the levels
of section. Results were expressed as the number of
glomeruli with positive staining for neutrophils, the aver-
age number of neutrophils per positive glomerular cross-
section, and the average number of neutrophils per all
glomerular cross-sections.
In Vivo Kinetics of Circulating Neutrophils after
Injected Anti-Neutrophil Antibodies
To evaluate the kinetics of neutrophil depletion, B6 mice
(n  7) were injected intraperitoneally with 1 mg of the
monoclonal rat anti-murine neutrophil antibody, NIMP-
R14, in 0.5 ml of PBS. NIMP-R14 selectively depletes
mouse neutrophils in vivo.12–14 The control groups (n  6)
received rat IgG (1 mg of IgG in 0.5 ml of PBS). Neutro-
phil depletion was assessed before injection and on day
1, 2, 3, 4, 5, and 6 after antibody injection by direct cell
counting of peripheral blood smears stained with Diff-
Quik Giemsa Stain Set (Dade Behring Inc., Newark, DE).
Effect of Neutrophil Depletion on the Induction
of Glomerulonephritis by Anti-MPO IgG
B6 mice (n  6) were injected intraperitoneally with 1 mg
of NIMP-R14 monoclonal antibody in 0.5 ml of PBS. The
control groups (n  6) received the same amount of
control rat IgG. Both experimental and control mice re-
ceived 50 g/g body weight of anti-mouse MPO IgG by
intravenous injection 16 hours after receiving the anti-
neutrophil antibodies. The effect of NIMP-R14 on periph-
eral blood leukocytes was determined by differential cell
counting of neutrophils, monocytes, and lymphocytes in
Diff-Quik Giemsa-stained peripheral blood smears. Intro-
duction of circulating anti-MPO was monitored by anti-
MPO enzyme-linked immunosorbent assay. The mice
were sacrificed on day 6 and kidney tissue processed for
light and immunofluorescence microscopy.
Statistical Analysis
Ranked analysis of variance and Kruskal-Wallis tests
were used to evaluate differences across groups, with
differences between specific groups evaluated within the
ranked analysis of variance test.
Results
Depletion of Circulating Neutrophils after
Injection of NIMP-R14 Monoclonal Antibodies
Within 1 day after a single injection of 1 mg of NIMP-R14
monoclonal antibody in 0.5 ml of PBS into B6 mice (n 
7), the number of circulating neutrophils was dramatically
reduced from 14% of white blood cells to 1%, and re-
Figure 1. Neutrophil depletion by NIMP-R14. B6 mice were injected either
with 1 mg of NIMP-R14 rat anti-murine neutrophil monoclonal antibody (n 
7) (open circles) or control rat IgG (n  6) (filled diamonds). Circulating
neutrophils were quantified at different time points by cell counting of blood
smears stained with Diff-Quik. Data are expressed as percentage of neutro-
phils in the blood. A single dose of the NIMP-R14 caused severe neutropenia
in mice for more than 5 days.
Figure 2. Neutrophil depletion prevents anti-MPO antibody-induced necrotizing and crescentic glomerulonephritis. B6 mice were pretreated with the neutrophil-
depleting antibody NIMP-R14 (n  6) or control rat IgG (n  6). Sixteen hours later, the mice received the pathogenic anti-MPO IgG (50 g/g body weight).
Mice were sacrificed for pathological examination 6 days after receiving anti-MPO IgG. All mice that received neutrophil-depleting antibodies and anti-MPO IgG
had normal glomeruli by light microscopy (left). In contrast, all mice that received control rat IgG and anti-MPO IgG developed segmental fibrinoid necrosis (long
arrow, middle, and arrow, right) and cellular crescents (short arrow, middle). Periodic acid-Schiff stain.
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mained at this low level for up to 5 days. Thereafter,
neutrophils gradually returned toward normal (Figure 1).
Control mice (n  6) injected with the same volume
of control IgG exhibited normal levels of circulating
neutrophils.
Prevention of Anti-MPO IgG-Induced NCGN by
Neutrophil Depletion
To directly determine whether neutrophils are required
for MPO-ANCA-mediated NCGN, B6 mice (n  6) were
pretreated with a single intraperitoneal injection of neu-
trophil-specific NIMP-R14 monoclonal antibody (1 mg
of IgG in 0.5 ml of PBS) before injection of anti-MPO
IgG. A differential leukocyte count of Giemsa-stained
blood smears 16 hours after the injection of NIMP-R14
antibody revealed 1.1  0.4% neutrophils, 1.1  0.4%
monocytes, and 97.8  0.6% lymphocytes. In contrast,
control mice had 14.0  4.4% neutrophils, 1.4  0.7%
monocytes, and 84.6  4.3% lymphocytes. The differ-
ence between the two groups was statistically different
for neutrophils (P  0.0001) and lymphocytes (P 
0.0001) but not for monocytes (P  0.2).
Sixteen hours after injection of either anti-neutrophil
(NIMP-R14) or control IgG, mice received an intrave-
nous injection of anti-MPO IgG. After 5 days, mice
injected with anti-MPO IgG without neutrophil depletion
developed urine abnormalities consistent with glomer-
ulonephritis, ie, 2.5  0.5 hematuria, 1.9  0.55 pro-
teinuria, and 0.8  0.8 leukocyturia. In contrast, mice
that were depleted of circulating neutrophils by pre-
treatment with NIMP-R14 anti-neutrophil antibodies
had urine analysis results that were within the refer-
ence ranges, ie, 0.2  0.4 hematuria, 1.0  0 protein-
uria, and 0  0 leukocyturia. Levels of circulating anti-
MPO IgG in the neutrophil-depleted mice were similar
to those found in the control mice (2.02  0.12 in
neutrophil-depleted mice with no NCGN versus 1.78 
0.72 in anti-MPO mice with NCGN (P  0.25).
All mice that were pretreated with normal rat IgG
before receiving anti-MPO rather than with NIMP-R14
developed focal glomerular necrosis (mean, 5.8 
1.1% of glomeruli with necrosis) and glomerular cres-
cents (mean, 11.5  2.8% of glomeruli with crescents)
whereas none of the mice that were pretreated with
NIMP-R14 developed glomerular necrosis or crescents
(Figure 2 and Table 1). Glomeruli that did not have
necrosis or crescents appeared normal by light mi-
croscopy with no hypercellularity and no increase in
matrix material.
Glomerular immunoglobulin and complement depo-
sition in mice that received anti-MPO alone was absent
or sparse and similar to that in mice that received
anti-MPO along with neutrophil depletion; and also was
similar to glomerular immunoglobulin and complement
localization in mice that received anti-BSA IgG or
healthy control mice that received no immunoglobulin
Figure 3. Glomerular leukocytes 6 days after injection of a single dose of
anti-MPO IgG. The panels show infiltration of an inflamed glomerulus by
neutrophils that are scattered throughout the tuft (top left marked with
anti-Gr-1), macrophages that are concentrated in the crescent (top right
marked with anti-CD68 and bottom right marked with anti-F4/80), and a
few lymphocytes (bottom left).
Table 1. Pathologic Findings in Mice that Received One Injection of Anti-MPO IgG, Anti-MPO IgG after Depletion of
























Anti-MPO 11.5 5.8 0.5 0.5 0.2 0.3 0.0 0.41* 0.86* 0.80* 0.10
2.8 1.1 0.0 0.0 0.3 0.3 0.0 0.11 0.05 0.22 0.03
Anti-MPO and 0 0 0.5 0.6 0.1 0.4 0.0 0.14 0.07 0.08 0.06
PMN depletion 0.0 0.2 0.2 0.2 0.0 0.06 0.03 0.02 0.04
Anti-BSA 0 0 0.5 0.50 0.2 0.5 0.0 0.11 0.08 0.09 0.07
0.0 0.0 0.3 0.0 0.0 0.04 0.05 0.04 0.03
B6 control 0 0 0.7 0.6 0.2 0.5 0.0 0.08 0.07 0.09 0.08
0.3 0.2 0.3 0.0 0.0 0.04 0.03 0.04 0.02
*P  0.002.
Pathologic findings in mice that received one dose of anti-MPO IgG (anti-MPO), anti-BSA IgG (anti-BSA), or no injection (B6 control). One set
of mice had depletion of neutrophils with NIMP-R14 before receipt of anti-MPO IgG (anti-MPO and PMN depletion). Crescent formation (Cres)
and necrosis are expressed as the percentage of glomeruli affected. Immunofluorescence microscopy staining of glomeruli is expressed as the
mean intensity of staining for IgG, IgM, IgA, C3, and MPO on a scale of 0 to 4. Immunoenzyme microscopy to detect glomerular neutrophils
(PMNs), monocytes, and macrophages (Mac) and lymphocytes (Lym) is expressed as average number of leukocytes per glomerular cross
section.
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(Table 1). Glomerular leukocyte phenotyping demon-
strated that mice that received anti-MPO without neu-
trophil depletion had statistically significant increased
glomerular infiltration by neutrophils and monocytes/
macrophages but not lymphocytes when compared to
control mice that received no immunoglobulin injec-
tions (Table 1). Neutrophils were most numerous in
glomeruli with inflammation and necrosis, and macro-
phages tended to cluster within crescents (Figure 3).
Mice that had neutrophil depletion before receiving
anti-MPO IgG and mice that received anti-BSA IgG had
no significant increase in neutrophils, monocytes/mac-
Figure 4. Glomerular neutrophil accumulation in B6 mice that received two doses of anti-MPO IgG on day 0 and day 3 followed by sacrifice on day 6. Mice that
received anti-BSA IgG had only rare neutrophils in a few glomeruli (not shown). Immunoenzyme microscopy using an antibody specific for mouse neutrophils
demonstrated that mice that received anti-MPO IgG had a marked increase in glomerular neutrophils especially at sites of necrosis or crescent formation. a: The
glomerulus has segmental fibrinoid necrosis (arrow) with brown-staining neutrophils most numerous at the margins of the necrosis. b: The glomerular tuft on
the left has scattered clusters of neutrophils and the hilar arteriole on the right (arrow) contains aggregated neutrophils. c: At the plane of section examined,
the glomerular tuft has a few scattered neutrophils and Bowman’s space contains numerous neutrophils (arrow). d: The glomerulus has extensive fibrinoid
necrosis (between arrows) with some residual neutrophils at the periphery in a crescent. Within the necrosis, there are scattered brown granules that probably
are neutrophil fragments.
Table 2. Pathologic Findings in Mice that Received Two Injections of Anti-MPO IgG or Anti-BSA IgG







Anti-MPO 12.0  6.1 17.8  7.8 30.27  6.98* 3.08  1.02* 0.97  0.48*
Anti-BSA 0.0 0.0 5.97  2.49 1.06  0.08 0.07  0.03
Mice received two doses of anti-MPO IgG (anti-MPO) or anti-BSA IgG (anti-BSA) on day 0 and day 3 with sacrifice on day 6. Crescent formation
and necrosis are expressed as the percentage of glomeruli affected. Immunoenzyme microscopy to detect glomerular neutrophils is expressed as
percentage of glomeruli with any neutrophils, average number of neutrophils per cross section of glomeruli with neutrophils, and average number of
neutrophils per cross section of all glomeruli.
*Neutrophil infiltration is significantly higher (P  0.001) in the anti-MPO group by all three methods of measuring glomerular infiltration.
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rophages, or lymphocytes when compared to control
mice (Table 1).
Glomerular Influx of Neutrophils after Induction
of Glomerulonephritis with Two Doses of
Anti-MPO IgG
To induce more robust glomerular injury, two doses of
anti-MPO were given at day 0 and day 3. These mice
developed hematuria (2.6), proteinuria (2.8), leukocy-
turia (1.4), and elevated blood urea nitrogen (45.2 mg/
dl) in contrast to the mice that received two doses of
anti-BSA IgG and had no significant elevation in hema-
turia (0), proteinuria (0.9), leukocyturia (0), or blood
urea nitrogen (25.5 mg/dl). The blood urea nitrogen in
mice that received anti-MPO was significantly elevated
over the blood urea nitrogen in the control mice (P 
0.04). By light microscopy, all mice that received anti-
MPO IgG had glomerular necrosis (average 17.8  7.8%
of glomeruli involved in each mouse) and crescents (av-
erage 12.0  6.1% of glomeruli involved) whereas mice
that received anti-BSA IgG had no renal histological ab-
normalities. Thus, these mice with two doses of anti-MPO
at days 0 and 3 had more severe glomerular injury with a
greater degree of necrotizing injury than mice that re-
ceived only one dose of anti-MPO IgG at day 0. However,
even in the mice that received two doses of anti-MPO,
most glomeruli had no abnormalities by light microscopy.
This is similar to acute focal human ANCA NCGN in which
glomeruli that do not have necrosis or crescents often
appear histologically normal.
Immunohistological staining of paraffin sections with
NIMP-R14 for neutrophils demonstrated that induction of
glomerulonephritis by anti-MPO IgG was accompanied
by glomerular influx of neutrophils (Table 2 and Figure 4).
Although increased neutrophils occurred in some glo-
meruli that had not yet developed histological lesions,
neutrophils were concentrated at sites of segmental ne-
crotizing glomerular injury, and occasionally were identi-
fied in Bowman’s space in glomeruli with necrosis or
crescents, and in a few afferent arterioles (Figure 4).
Positively staining fragments of neutrophils were present
in some necrotic areas (Figure 4d).
Discussion
In this mouse model of ANCA NCGN, neutrophils and
macrophages are present at the sites of acute glomerular
injury, and neutrophil depletion completely protects mice
from induction of NCGN by anti-MPO IgG even in the
presence of levels of circulating anti-MPO IgG that cause
NCGN in 100% of mice with normal levels of neutrophils.
These observations support the concept that neutrophils
are the key effector cells in anti-MPO antibody-induced
NCGN.
Numerous in vitro studies have documented the ability
of human ANCA IgG (ie, both anti-MPO and anti-PR3
IgG) to activate neutrophils with the resultant release of
toxic oxygen metabolites, lytic and toxic proteases, nitric
oxide, and inflammatory cytokines.15–19 This activation
involves increased display of ANCA antigens at the sur-
face of neutrophils facilitating both the attachment of the
antigen-binding portion of the autoantibodies as well as
the engagement of Fc receptors on the surface of neu-
trophils.20–22 Neutrophils that have been activated by
ANCA IgG adhere to and kill endothelial cells in vivo23–25
and are induced to migrate through endothelial monolay-
ers.26 If these events that have been observed repeat-
edly in vitro are reproduced in vivo by ANCA IgG-induced
stimulation on neutrophils, this would provide a clear
pathogenic mechanism for the mediation of acute inflam-
matory vascular injury, including glomerulonephritis and
vasculitis, by activation of neutrophils by ANCA IgG.8
The experiments reported here provide evidence for
an important role for neutrophils in this experimental
model, but they do not rule out the participation of mono-
cytes in disease induction. Monocytes express both MPO
and PR3 and can be activated by ANCA IgG to release
many of the same mediators that are released by neutro-
phils after activation by ANCA.27–30 Under the conditions
tested in the current model, any activation of monocytes
that may be occurring is not sufficient to produce detect-
able injury in the absence of neutrophils. However, the
immunophenotyping of leukocytes demonstrated the
clear participation of macrophages in the necrotizing and
especially the crescentic lesions. One possibility is that
the initial induction of acute necrotizing injury is primarily
mediated by neutrophils, whereas the macrophage infil-
tration is a component of the innate inflammatory re-
sponse to the injury and plays a major role in the initiation
of crescent formation. The leukocyte phenotyping re-
vealed only a few lymphocytes at the sites of acute injury.
This lack of substantial participation of lymphocytes in the
acute injury is consistent with the observation that this
model of glomerulonephritis can be induced by injecting
anti-MPO IgG into immune-deficient mice that lack func-
tional T cells.10
In summary, our results demonstrate that neutrophils
are crucial in the induction of NCGN by anti-MPO anti-
bodies in this experimental model. This supports the
possibility that neutrophils are similarly important in hu-
man ANCA NCGN. If this is the case, therapeutic strate-
gies that target ANCA-induced neutrophil recruitment
and activation could be beneficial in the treatment of
ANCA diseases.
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